AEON Biopharma Files 8-K

Ticker: AEON · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1837607

Sentiment: neutral

Topics: regulatory-filing, financials

TL;DR

AEON Biopharma filed an 8-K on Sept 8, 2025, covering Reg FD and financials. Old name: Priveterra Acquisition Corp.

AI Summary

AEON Biopharma, Inc. filed an 8-K on September 8, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020, is incorporated in Delaware and headquartered in Irvine, California.

Why It Matters

This filing provides an update on AEON Biopharma's regulatory disclosures and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing for regulatory and financial disclosures, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for AEON Biopharma, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.

When was AEON Biopharma, Inc. formerly known as?

AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp.

On what date was the name change from Priveterra Acquisition Corp. to AEON Biopharma, Inc. effective?

The date of the name change was December 22, 2020.

In which state is AEON Biopharma, Inc. incorporated?

AEON Biopharma, Inc. is incorporated in Delaware.

What is the principal executive office address for AEON Biopharma, Inc.?

The principal executive office address is 5 Park Plaza, Suite 1750, Irvine, CA 92614.

Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-08 17:00:33

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 8, 2025, AEON Biopharma, Inc. (the "Company" or "AEON") made available in the investor relations section of its website a presentation (the "Corporate Presentation"), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled "Forward-Looking Statements" in Exhibit 99.1 attached hereto. The information furnished in this Item 7.01 of this Current Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated September 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: September 8, 2025 By: /s/ Robert Bancroft Robert Bancroft Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing